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Abstract
Background: Plasmablastic lymphoma (PL) is a subtype of diffuse large B-cell lymphoma (DLBCL).
Studies have suggested that tumors with PL morphology represent a group of neoplasms with
clinopathologic characteristics corresponding to different entities including extramedullary
plasmablastic tumors associated with plasma cell myeloma (PCM). The goal of the current study
was to evaluate the genetic similarities and differences among PL, DLBCL (AIDS-related and non
AIDS-related) and PCM using array-based comparative genomic hybridization.
Results: Examination of genomic data in PL revealed that the most frequent segmental gain (>
40%) include: 1p36.11-1p36.33, 1p34.1-1p36.13, 1q21.1-1q23.1, 7q11.2-7q11.23, 11q12-11q13.2
and 22q12.2-22q13.3. This correlated with segmental gains occurring in high frequency in DLBCL
(AIDS-related and non AIDS-related) cases. There were some segmental gains and some segmental
loss that occurred in PL but not in the other types of lymphoma suggesting that these foci may
contain genes responsible for the differentiation of this lymphoma. Additionally, some segmental
gains and some segmental loss occurred only in PL and AIDS associated DLBCL suggesting that
these foci may be associated with HIV infection. Furthermore, some segmental gains and some
segmental loss occurred only in PL and PCM suggesting that these lesions may be related to
plasmacytic differentiation.
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Journal of Hematology & Oncology 2009, 2:47 http://www.jhoonline.org/content/2/1/47Conclusion: To the best of our knowledge, the current study represents the first genomic
exploration of PL. The genomic aberration pattern of PL appears to be more similar to that of
DLBCL (AIDS-related or non AIDS-related) than to PCM. Our findings suggest that PL may remain
best classified as a subtype of DLBCL at least at the genome level.
Findings
Plasmablastic lymphoma (PL), one of the most frequent
oral malignancies in human immunodeficiency virus
(HIV) infected patients, was first characterized by Delec-
luse et al [1]. They proposed that this constituted a new
subtype of diffuse large B cell lymphoma (DLBCL); it was
suggested as a distinct entity based on its blastic morphol-
ogy, its clinical behavior involving predominantly
extramedullary sites (particularly oral cavity), and its lim-
ited antigenic phenotype data suggesting differentiation
toward plasmacytic differentiation (CD20-, CD79a+ and
VS38c+). The incidence of PL has increased following the
introduction of highly active antiretroviral therapy
(HAART) [2,3]. By WHO Classification, PL is categorized
as a subtype of DLBCL associated with HIV and Epstein-
Barr virus [1,4,5].
Recent morphologic and immunohistochemical studies,
however, have suggested that tumors with PL morphology
may represent a heterogeneous group of neoplasms with
different clinicopathologic characteristics, corresponding
to different entities including PL, DLBCL with plasmacytic
differentiation, and extramedullary plasmablastic tumors
associated with plasma cell myeloma (PCM) [6,7]. To fur-
ther delineate the relationship between PL, DLBCL and
PCM, we evaluated the genetic lesions among PL, DLBCL
(AIDS-related and non AIDS-related) and PCM using
array-based comparative genomic hybridization (array
CGH) technology [8,9].
Materials and methods
Archived formalin-fixed paraffin-embedded blocks of PL
(n = 16, demographic data in Table 1), DLBCL (AIDS-
related, n = 13; non-AIDS-related, n = 13) and PCM (n =
8) were retrieved from Department of Pathology at The
Methodist Hospital or Baylor College of Medicine (BCM),
AIDS and Cancer Specimen Resource and Hematopathol-
ogy Section, Laboratory of Pathology, National Cancer
Institute. The use of these materials was approved by the
Institutional Review Boards of participating institutions.
One H&E section of each case was reviewed to confirm
that more than 80% of cells were neoplastic cells. DNA
was then extracted from the consecutive section of each
case or sections of paraffin embedded reactive tonsils (as
control) using DNAeasy kit (Quiagen, Valencia, CA). For
each sample, tumor DNA and control DNA was the
labeled with Cy5 or Cy3 reversely in the replicate experi-
ment (i.e. dye swap) to address the confounding effect of
the dye and experiment and hybridized to array slides
containing 2621 BAC clones at an average of 1-Mbp reso-
lution (SpectralChip 2600 array, PerkinElmer, Waltham,
MA) according to the manufacturer's protocol. The slides
were imaged using an Axon 4000B scanner and GenePix
Pro 6.0 scanning software.
After scanning of the slide, the fluorescent intensities of
the Cy3 and Cy5 channels were background subtracted.
The resulting values were normalized by intensity based
local weighted regression method (Lowess) to correct for
systematic bias in dye labeling and fluorescent intensity
Table 1: Demographic data, HIV status and location of disease in 
cases with plasmablastic lymphoma
Gender Age HIV Status Location
F 11 + GI
M 44 + Skin
M 38 ? ?
M 66 ? Left nasal cavity
M 63 + Gluteal mass
M 40 + Epidural mass
M 36 + Left nasal cavity
M 55 + Oral cavity
M 55 - LN
M 82 - LN
M 51 + Gall bladder
M 37 ? ?
F 56 + Oral cavity
M 47 + Anal
M 77 - Maxillary sinus
M 37 + LNPage 2 of 6
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was calculated and log base 2 transformed (log ratios).
After normalization, values for duplicated spots represent-
ing one clone were averaged. For each case, clones were
excluded from further analysis if their values for forward
hybridization failed to show reciprocal changes with the
dye-reversed hybridization or if they were with 10% or
more polymorphism within a normal population http://
projects.tcag.ca/variation/. The top 75 clones showing
highest degrees of gain or loss based on log2 ratio were
then selected for each case. The neighboring clones (based
on cytoband positioning) of the selected clones were fur-
ther examined and three consecutive BAC clones with the
same change (gain or loss) were selected as a segment of
gain or loss. The frequencies of segmental gains and losses
among different types of tumors were recorded. Two PL
cases were also validated by 10K SNP array by Affymetrix
as described previously [11]. The gains of 16p13.3 in PL
cases were further validated with FISH using RP11-
417B20 BAC clone with the methods published previ-
ously [12].
Results and Discussions
To the best of our knowledge, the current study represents
the first genomic exploration of plasmablastic lymphoma,
a rare type of lymphoma occurring commonly in oral cav-
ity of AIDS patients. In the PL cases, segmental gains and
losses ranging in size from 0.2 Mb to 37.7 Mb and 0.2 Mb
to 27.7 Mb, respectively, were detected in all specimens.
On average, 12.63 +/- 5.92 (range, 6 - 29) segmental gains
per specimen were detected, with slightly fewer segmental
losses per specimen (mean +/- SD = 6.94 +/- 4.22; range,
1 - 16 segmental losses). Recurring (common) segmental
gain or loss (occurring in at least 2 cases) were detected on
all autosomes except chromosome 12, ranging in size
from 0.7 Mb to 15.9 Mb for gain and from 0.5 Mb to 16.4
Mb for loss (Table 2). The most frequent segmental gains
(> 40%) in PL include: 1p36.11-1p36.33, 1p34.1-
1p36.13, 1q21.1-1q23.1, 7q11.2-7q11.23, 11q12-
11q13.2 and 22q12.2-22q13.3. However, the segmental
losses were more heterogeneous with frequencies up to
only 23% (Table 2).
Overall, the genomic aberration pattern of PL is more sim-
ilar to that of DLBCL (AIDS-related or non-AIDS-related)
than to that of PCM (measured by Pearson correlation
coefficient, Figure 1A). One of the altered chromosomal
regions identified by CGH [gain of 16p13.3, frequently
occurring in PL (6/16), DLBCL (AIDS-related, 7/13 or
non-AIDS-related, 10/13) but not in PCM, 0/8] was vali-
dated by FISH analysis (Figure 1B). FISH performed in
subsets of cases including 6 cases of PL and 6 cases of mye-
loma showed gain of this region in 3 of 6 PL cases but in
none of myeloma cases. Of note, our previous immuno-
histochemical studies using a limited panel of antibodies
showed that PL and PCM had almost identical immu-
nophenotypic patterns which are quite different from
those of DLBCL [7]. However, the results of the current
study suggest that PL is best classified as a subtype of
DLBCL at least at the genomic level. However, it should be
noted that most of PL cases studied do not arise from oral
cavities. It would be of great interest to study more cases
of oral cavity PL in the future to further confirm our obser-
vation.
Additionally, it would be of great interest to further corre-
late the array CGH findings with gene expression profiling
of these types of lymphoma's to further clarify the rela-
tionship among these types of lymphoma. Also, it would
have been important to study the similarity and difference
between HIV+ or HIV- PL cases versus HIV+ group of
DLBCL, as well as HIV- group of DLBCL. However, in the
current study, the HIV negative PL cases were too few in
our cohort and make this comparison impossible. Future
studies to include more HIV negative PL cases are indi-
cated to illustrate this important issue.
Potential biomarkers for diagnosing PL are suggested by
our approach. Several segmental gains in 1p35.1-1p36.12
(10 of 16 cases or 10/16), 1q21.1-1q23.1 (8/16),
1p36.11-1p36.33 (7/16), were only present in PL but not
in other cases (PL vs. others, p < 0.05 for lesions shown,
Fisher's exact test with correction for false discovery rate
using the Benjamini and Hochberg method [13]). BAC
clones in these regions, including RP5-886K2, RP3-
462O23, RP11-452O22, RP11-77I10, RP3-491M17,
RP11-33M12, RP3-438L4, RP11-219C24, RP4-726F20,
may be further developed for the diagnosis of PL using
FISH technology. As mentioned, by morphologic and
immunohistochemical evaluation, features of PL overlap
significantly with DLBCL and PCM [7]. Additionally,
these regions contain important oncogenes such as:
PRAME, PDPN, COPA, and NHLH1 [14-17]. Of interest,
segmental gains of 16p12-16p13.2 and 11q14-11q14,
occurred more frequently in HIV positive cases suggesting
that these lesions may be related to HIV associated malig-
nancies (PL-HIV+ = 4/10 and AIDS-related DLBCL = 9/13
vs. 1/27 HIV-negative cases for 16p12-16p13.2 and PL-
HIV+ = 3/10 and AIDS-related DLBCL = 12/13 vs. 1/27
HIV-negative cases for 11q14-11q14, p < 0.05, Fisher's
exact test with correction for false discovery rate using the
Benjamini and Hochberg method [13]). The potential
candidate genes include PLA2 [18]. This gene has been
shown to be activated by HIV envelope glycoproteins and
may participate in the fusion of HIV and lymphocytes.
Studies to investigate the roles of this gene and other
genes in these regions in HIV-related PL and/or AIDS-
related DLBCL are indicated.Page 3 of 6
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Chromosome Cyto band Size, Mbp No. clones Freq, %
Gain
1 1p36.11-1p36.33 8.3 10 44
1p34.1-1p36.13 5.6 7 63
1q21.1-1q23.1* 10.5 9 50
1q42.1-1q43* 8 8 19
2 2p22-2p23* 0.7 3 13
2p14-2p16* 2.7 3 13
3 3p14.3-3p21.32* 7.5 6 13
3q26-3q26.3* 3 3 13
4 4p16.1-4p16.3 0.8 4 13
6 6p22-6p24.3* 9.9 11 13
7 7p21.3-7p23* 2.4 4 38
7q11.2-7q11.22* 3.1 6 25
7q11.2-7q11.23* 3.8 4 50
8 8p21.3-8p22 2.5 3 13
8p12-8p12 1.5 3 13
8q24.3-8qter 3.7 3 25
9 9q34.2-9q34.3* 2.2 4 13
10 10p12-10p12.33 2.9 3 23
10q21.2-10q22.1 2.3 5 19
11p12-11p13* 1 3 13
11q12-11q13.2* 8.7 8 44
11q13.4-11q14* 7.5 10 25
13 13q33.3-13q34* 1.1 4 13
14 14q21.1-14q21.3 3.2 4 13
14q32.32-14q32.33 0.9 5 31
15 15q22-15q22 4.5 3 13
16 16p13.2-16p13.3* 4.6 8 38
16p13.1-16p13.3* 8.6 11 19
16p12-16p13.1* 8 5 25
16p11.2-16p12.1* 7.1 5 13
16q12.1-16q12.2 2.9 4 19
16q21-16q22* 5.2 4 13
16q24-16q24* 2.5 3 13
16q24.1-16q24* 4.2 6 38
17 17p13-17p13.3* 2 8 38
17p13.2-17p13.3* 5.3 9 31
17q24-17q25.1* 3.1 6 19
19 19p13.12-19p13.3* 15.9 12 44
20 20q11.1-20q11.23 2.7 4 38
20q12-20q13.3* 2.9 5 19
20q13.2-20q13.33* 2 4 25
21 21q22.2-21q22.3* 5 3 13
22 22q11.1-22q11.22* 1.5 4 19
22q12.2-22q13.3* 7.9 8 56
Loss
1 1p36.11-1p36.33* 8.3 10 13
1p31.2-1p33* 0.6 5 13
1p31.1-1p32.1* 3.7 4 19
1p22-1p31.2* 1.4 3 19
1p13.3-1p22.3 0.5 3 13
1q31.1-1q32.1 1.8 3 13
2 2q22-2q23.1* 2.4 3 13
2q31-2q32.3 16.4 12 13
3 3p12-3p14.1 9.6 10 13
4 4q32.1-4q32.3* 11.7 9 13
5 5p14-5p14.3 4 6 23
6 6q16.2-6q16.2* 1.4 4 13
7 7q31-7q32.1 4.4 4 13
8 8q12.1-8q12.3 4.4 4 13
8q24.2-8q24.3 3 4 13Page 4 of 6
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11 11q22-11q22.3 5.1 6 19
17 17p11.1-17p12* 5.2 6 13
18 18q11.2-18q12 3.1 3 13
18q12-18q12.3 5.1 3 13
18q22-18q22.1* 3 4 13
20 20p12.2-20p13 0.8 4 13
20p12-20p12.2 2.2 7 19
20p12-20p12.2 2.3 3 13
20q13.11-20q13.33 5.1 5 13
* Regions also reported to show gain or loss in diffuse large B-cell lymphoma by CHEN et al[19].
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Plasmablastic lymphoma (PL) is more similar to diffuse large B-cell lymphoma (DLBCL) and AIDS-related DLBCL (AIDS-DLBCL) than plasma cell myelo a (PCM)Figure 1
Plasmablastic lymphoma (PL) is more similar to diffuse large B-cell lymphoma (DLBCL) and AIDS-related 
DLBCL (AIDS-DLBCL) than plasma cell myeloma (PCM). A. Upper panel: The heatmap of genomic lesions by array 
CGH among 4 groups of lymphoma studied. The left column shows the number of chromosomes. The right column shows the 
frequencies of gains (represented by positive values) or loss (represented by negative values). Lower panel: The Pearson corre-
lation coefficient among different groups of lymphomas. B. FISH validation of gains of 16p13.3 frequently identified in PL cases 
by array CGH. Shown is the interphase cells hybridized with RP11-88L24 (2q31.2/Red) as control and RP11-417B20 (16p31.2/
Green) in a representative case. A magnified image of an interphase cell showing three copies of RP11-417B20 and two copies 
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Using the same platform of BAC array CGH on DNA
extracted from frozen tissue samples, Chen et al have
recently reported many genomic gains and losses in
DLBCL [19]. Most (55.17%) of the regions identified by
Chen el al were also identified in our cases of DLBCL
(AIDS- or non-AIDS-related). Similarly, our CGH studies
of PCM produce similar findings to the study of Carrasco
et al, who used the oligonucleotide format by Agilent
Technologies (data not shown) [20]. These findings fur-
ther support the validity of the CGH data obtained using
paraffin-embedded tissues.
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